T. Cd4 and T. Cd8, Treg) est analysée sur des critères phénotypiques (CD39, CD73, PD-1, Tim-3) et fonctionnels (IFN-?, Chacune de populations sélectionnées

, Chacune de populations sélectionnées (LB, NK, T??) est analysée sur des critères phénotypiques (CD39, CD73, PD-1) et fonctionnels (IFN-?, CD107a)

, Chacune de populations sélectionnées (DC, monocytes, MDSCs) est analysée sur des critères phénotypiques (CD39, CD73) et fonctionnels

, Stratégie d'analyse des populations immunitaires Humaines

T. Cd4, T. Cd8, L. B. , N. K. , and D. C. , MDSCs) est analysée sur des critères phénotypiques (CD39, CD73, PD-1, Tim-3) et fonctionnels (IL-2, IFN-?, CD107a)

, Publications Internationales à comité de lecture

H. Michaud, O. Becquart, V. Lafont, B. Guillot, F. Boissière-michot et al., « PD-1 Blockade at the Time of Tumor Escape Potentiates the Immune-Mediated Antitumor Effects of a Melanoma-Targeting Monoclonal Antibody » Laetitia They, vol.6, p.1353857, 2017.

«. Il, 21 Promotes the Development of a CD73-Positive V?9V?2 T Cell Regulatory Population

C. Barjon, H. Michaud, A. Fages, C. Dejou, A. Zampieri et al., Oncoimmunology, vol.7, issue.1, p.1379642, 2017.

, Microcavity Formation and Lesion Volume After Severe Spinal Cord Injury ». Noristani, Harun Najib, Laetitia They, et Florence Evelyne Perrin, « C57BL/6 and Swiss Webster Mice Display Differences in Mobility, Gliosis, vol.12, 2018.

, Strenghtening the immunomodulatory effects of anti-tumor monoclonal antibody using an anti-immune checkpoint inhibitor in melanoma. 2018: Potentiation of immunomodulatory effects of an anti-tumor monoclonal antibody. Présentation aux Journées des Etudiants en Thèse de l'IRCM (JET) 2016: The immunomodulatory effects of an anti-tumor monoclonal antibody in melanoma. 2018: Potentiation of immunomodulatory effects of an anti-tumor monoclonal antibody, Présentation aux retraites du Labex MAbImprove : 2016: Strenghtening the immunomodulatory effects of anti-tumor monoclonal antibody: Study of potentiating effects of combined therapies and analysis of the mechanisms involved, 2017.

, Présentation à la Journée de l'Ecole Doctorale CBS2 (CBS2 Day) 2018: Potentation of immunomodulatory effects of an anti-tumor monoclonal antibody

, 2016: Characterization of long-term protective immunity after anti-tumor-based immunotherapy in melanoma

, Présentation à la 12 ème Journée Cancéropôle Grand Sud-Ouest (GSO) 2016: PD-1 blockade potentiates immunomodulatory functions of a tumor antigen targeting monoclonal antibody, Prix du meilleur poster, Fondation SILAB Jean-Paufique

, Participation à l'organisation des journées scientifiques de l'ED CBS2 des éditions 2016, 2017.

, Bénévole et participante (table ronde) au 17 ème colloque de Femmes & Sciences édition, 2017.

R. Abès, E. Gélizé, W. Herman-fridman, and J. Teillaud, « LongLasting Antitumor Protection by Anti-CD20 Antibody through Cellular Immune Response, Blood, vol.116, issue.6, p.92634, 2010.

I. Acerbi, . Cassereau, . Dean, . Shi, C. Au et al., « Human Breast Cancer Invasion and Aggression Correlates with ECM Stiffening and Immune Cell Infiltration, Integrative biology : quantitative biosciences from nano to macro, vol.7, p.112034, 2015.

J. M. Adams, S. Et, and . Cory, « The Bcl-2 Apoptotic Switch in Cancer Development and Therapy, Oncogene, vol.26, issue.9, p.132437, 2007.

. Ahmadzadeh, L. A. Mojgan, B. Johnson, J. R. Heemskerk, . Wunderlich et al.,

D. E. Dudley, S. A. White, and . Rosenberg, « Tumor Antigen-Specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and Are Functionally Impaired, Blood, vol.114, issue.8, p.153744, 2009.

R. J. Akhurst, R. Et, and . Derynck, « TGF-Beta Signaling in Cancer, Trends in Cell Biology, vol.11, issue.11, pp.44-51, 2001.

J. Albrengues, G. Meneguzzi, and C. Gaggioli, , 2014.

, , vol.30

E. Aliagas, A. Vidal, L. Texidó, and J. Ponce, « High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors ». Research article. Mediators of Inflammation, 2014.

E. Alici, « IPH-2101, a Fully Human Anti-NK-Cell Inhibitory Receptor MAb for the Potential Treatment of Hematological Cancers, Current Opinion in Molecular Therapeutics, vol.12, issue.6, p.72433, 2010.

B. Allard, S. Pommey, and M. J. Smyth, et John Stagg. 2013. « Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 MAbs

L. Amable, « Cisplatin resistance and opportunities for precision medicine, Pharmacological Research, vol.106, p.2736, 2016.

. Amin, D. H. Asim, A. K. Lawson, H. B. Salama, T. Koon et al.,

S. J. Thomas and . O'day, « Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma », Journal for ImmunoTherapy of Cancer, vol.4, issue.1, p.44, 2016.

S. Andreae, F. Piras, N. Burdin, F. Et, and . Triebel, « Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223), The Journal of Immunology, vol.168, issue.8, p.387480, 2002.

L. P. Andrews, A. E. Marciscano, C. G. Drake, A. A. Dario, and . Vignali, LAG3 (CD223) as a Cancer Immunotherapy Target, vol.276, pp.80-96, 2017.

. Antonioli, G. G. Luca, P. Yegutkin, C. Pacher, . Blandizzi et al., Anti-CD73 in cancer immunotherapy: awakening new opportunities, vol.2, p.95109, 2016.

L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz et al., « Toll-like Receptor 4-Dependent Contribution of the Immune System to Anticancer Chemotherapy and Radiotherapy », Nature Medicine, vol.13, issue.9, p.105059, 2007.

M. Aris, M. M. Barrio, J. Et, and . Mordoh, « Lessons from Cancer Immunoediting in Cutaneous Melanoma ». Research article, Journal of Immunology Research, 2012.

P. Aroca, F. Solano, J. C. Garcia-borrón, and J. A. Lozano, Specificity of Dopachrome Tautomerase and Inhibition by Carboxylated Indoles. Considerations on the Enzyme Active Site, vol.277, p.39397, 1991.

P. A. Ascierto, P. Bono, S. Bhatia, I. Melero, M. S. Nyakas et al., « LBA18Efficacy of BMS-986016, a Monoclonal Antibody That Targets Lymphocyte Activation Gene-3 (LAG-3), in Combination with Nivolumab in Pts with Melanoma Who Progressed during Prior Anti-PD-1/PD-L1 Therapy, All-Comer and Biomarker-Enriched Populations, vol.28, 2017.

M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss et al.,

, « High-Dose Recombinant Interleukin 2 Therapy for Patients with Metastatic Melanoma: Analysis of 270 Patients Treated between 1985 and, vol.17, p.210516, 1993.

M. B. Atkins, « IMMUNOTHERAPY AND EXPERIMENTAL APPROACHES FOR METASTATIC MELANOMA ». Hematology/Oncology Clinics of North America, vol.12, issue.4, p.902, 1998.

T. Balatoni, A. Mohos, E. Papp, T. Sebestyén, G. Liszkay et al., « Tumor-Infiltrating Immune Cells as Potential Biomarkers Predicting Response to Treatment and Survival in Patients with Metastatic Melanoma Receiving Ipilimumab Therapy, Cancer Immunology, Immunotherapy, vol.67, issue.1, p.14151, 2018.

F. Baratelli, Y. Lin, L. Zhu, S. Yang, N. Heuzé-vourc'h et al., , 2005.

, « Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells », vol.175, p.148390, 1950.

I. B. Barsoum, C. A. Smallwood, D. R. Siemens, and C. H. Graham, « A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells, Cancer Research, vol.74, issue.3, p.66574, 2014.

J. Bastid, A. Regairaz, N. Bonnefoy, C. Déjou, J. Giustiniani et al., « Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity, Cancer Immunology Research, vol.3, issue.3, p.25465, 2015.

P. A. Beavis, U. Divisekera, C. Paget, M. T. Chow, L. B. John et al., Blockade of A 2A Receptors Potently Suppresses the Metastasis of CD73 + Tumors, vol.110, p.1471116, 2013.

D. M. Benson, C. E. Bakan, S. Zhang, S. M. Collins, J. Liang et al., IPH2101, a Novel Anti-Inhibitory KIR Antibody, and Lenalidomide Combine to Enhance the Natural Killer Cell versus Multiple Myeloma Effect, vol.118, p.638791, 2011.

J. Benzaquen, C. Marquette, N. Glaichenhaus, S. Leroy, P. Hofman et al., , 2018.

, « Rationnel biologique de l'immunothérapie des cancers, vol.35, p.20622

G. Bergers and S. Song, « The role of pericytes in blood-vessel formation and maintenance, Neuro-Oncology, vol.7, issue.4, p.45264, 2005.

F. Bertrand, J. Rochotte, C. Colacios, A. Montfort, A. Tilkinmariamé et al., « Blocking Tumor Necrosis Factor ? Enhances CD8 T-Cell-Dependent Immunity in Experimental Melanoma, 2015.

H. Bid and . Kumar, « Re: Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy, European Urology, vol.67, issue.2, p.351, 2015.

M. Bilzer, A. L. Et, and . Gerbes, « Verminderung der experimentellen Hepatitis durch den GProtein-gekoppelten Adenosin-A2-Rezeptor, Zeitschrift für Gastroenterologie, vol.40, issue.07, p.543, 2002.

,

S. A. Birkeland, H. Hans, L. U. Storm, L. Lamm, I. Barlow et al., Cancer Risk after Renal Transplantation in the Nordic Countries, vol.60, p.18389, 1964.

S. D. Blackburn, W. N. Haina-shin, T. Haining, C. J. Zou, A. Workman et al., , 2009.

, « Coregulation of CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors during Chronic Viral Infection », Nature Immunology, vol.10, issue.1, p.2937

R. Boissier, E. Et, and . Gross, « La radiothérapie hypofractionnée dans le traitement du cancer de prostate : irradier moins pour traiter plus, Progrès en Urologie, vol.22, issue.6, p.32630, 2012.

H. Borghaei, C. J. Langer, S. Gadgeel, V. A. Papadimitrakopoulou, A. Patnaik et al., « LBA49Updated Results from KEYNOTE-021 Cohort G: A Randomized, Phase 2 Study of Pemetrexed and Carboplatin (PC) with or without Pembrolizumab (Pembro) as First-Line Therapy for Advanced Nonsquamous NSCLC, Annals of Oncology, vol.28, 2017.

A. Bozec, M. M. Zaiss, R. Kagwiria, R. Voll, M. Rauh et al., T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway, vol.6, pp.235-60, 2014.

L. Bracci, F. Moschella, P. Sestili, V. L. Sorsa, M. Valentini et al., « Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.13, issue.2, p.64453, 2007.

V. Brichard, A. Van-pel, T. Wölfel, C. Wölfel, E. De-plaen et al.,

. «-the-tyrosinase, Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas, vol.178, p.489

C. Brignone, B. Escudier, and C. Grygar,

«. Phase, Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.15, p.622531

C. Brignone, C. Grygar, M. Marcu, G. Perrin, F. Et et al., « IMP321 (SLAG-3), an Immunopotentiator for T Cell Responses against a HBsAg Antigen in Healthy Adults: A Single Blind Randomised Controlled Phase I Study, Journal of Immune Based Therapies and Vaccines, vol.5, 2007.

P. Bruggen, C. Van-der, P. Traversari, C. Chomez, E. Lurquin et al., A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma, vol.254, p.164347, 1991.

J. F. Brunet, F. Denizot, M. F. Luciani, M. Roux-dosseto, M. Suzan et al., A New Member of the Immunoglobulin Superfamily-CTLA-4, vol.328, p.26770, 1987.

. Bubeník, « MHC Class I Down-Regulation: Tumour Escape from Immune Surveillance? (Review), International Journal of Oncology, vol.25, issue.2, p.48791, 2004.

M. Burnet, « Cancer-A Biological Approach, British Medical Journal, vol.1, issue.5022, p.77986, 1957.

V. Calugaru and N. Magné,

J. Thariat, Nanoparticules et radiothérapie, vol.102, p.8391, 2015.

D. A. Cameron, R. Cornbleet, J. Mackie, . Hunter, . Gore et al.,

, Adjuvant interferon alpha 2b in high risk melanoma-the Scottish study, British Journal of Cancer, vol.84, issue.9, p.114649

A. B. Campo, J. Del, N. Carretero, E. F. Aptsiauri, and . Garrido, « Targeting HLA Class I Expression to Increase Tumor Immunogenicity, Tissue Antigens, vol.79, issue.3, p.14754, 2012.

G. Cartron, H. Watier, J. Golay, P. Et, and . Solal-celigny, « From the Bench to the Bedside: Ways to Improve Rituximab Efficacy, Blood, vol.104, issue.9, p.263542, 2004.

N. Casares, M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux et al., « Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, The Journal of Experimental Medicine, vol.202, issue.12, pp.1691-1701, 2005.

A. Cauwels, S. Van-lint, F. Paul, G. Garcin, . Stefaan-de et al., « Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments », Cancer Research, vol.78, issue.2, p.46374, 2018.

F. Cavallo, C. D. Giovanni, P. Nanni, G. Forni, P. Et et al., The Immune Hallmarks of Cancer, Cancer Immunology, Immunotherapy, vol.60, issue.3, p.319, 2011.

,

P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, vol.364, p.250716, 2011.

L. Chen and . Et-xue-han, Anti-PD-1/PD-L1 Therapy of Human Cancer: Past, Present, and Future, vol.125, p.338491, 2015.

I. Chevolet, R. Speeckaert, M. Haspeslagh, B. Neyns, V. Krüse et al., « Peritumoral Indoleamine 2,3-Dioxygenase Expression in Melanoma: An Early Marker of Resistance to Immune Control?, The British Journal of Dermatology, vol.171, issue.5, p.98795, 2014.

R. Chicas-sett, I. Morales-orue, D. Rodriguez-abreu, and P. Lara-jimenez,

, Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review, Clinical and Translational Radiation Oncology, vol.9, p.511

A. Coates, S. Abraham, S. B. Kaye, T. Sowerbutts, C. Frewin et al.,

, On the Receiving End-Patient Perception of the Side-Effects of Cancer Chemotherapy, European Journal of Cancer & Clinical Oncology, vol.19, issue.2, p.2038

W. B. Coley, « The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proceedings of the Royal Society of Medicine, vol.3, p.148, 1910.

L. M. Coussens, Z. Et, and . Werb, « Inflammation and Cancer ». Special Features. Nature. 19 décembre, 2002.

B. D. Curti, M. Kovacsovics-bankowski, N. Morris, E. Walker, L. Chisholm et al., « OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients, Cancer Research, vol.73, issue.24, p.718998, 2013.

H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins et al., « Mutations of the BRAF Gene in Human Cancer », Nature, vol.417, issue.6892, p.94954, 2002.

M. Dewan, A. E. Zahidunnabi, N. Galloway, J. K. Kawashima, J. S. Dewyngaert et al., « Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect When Combined with AntiCTLA-4 Antibody, Clinical Cancer Research, vol.15, issue.17, p.537988, 2009.

D. Francesco, A. M. , A. Ruggiero, and E. R. Riccardi, Cellular and Molecular Aspects of Drugs of the Future: Oxaliplatin ». Cellular and Molecular Life Sciences: CMLS 59, p.1914, 2002.

L. Dias, . Paro, C. M. Ângela, B. B. Luzo, M. Volpe et al., « Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer, Tissue and Cell, vol.52, p.1727, 2018.

D. J. Dilillo, K. Yanaba, F. Thomas, and . Tedder, « B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16, 2010.

, Melanoma Growth in Mice ». Journal of Immunology, vol.184, issue.7, p.400616, 1950.

. Dilruba, . Shahana, V. Ganna, and . Kalayda, « Platinum-Based Drugs: Past, Present and Future, Cancer Chemotherapy and Pharmacology, vol.77, issue.6, p.110324, 2016.

. Dimova, G. Ivanka, V. Popivanov, and . Djonov, « Angiogenesis in CancerGeneral Pathways and Their Therapeutic Implications, vol.19, p.1521, 2014.

. Dong, S. E. Haidong, D. R. Strome, H. Salomao, F. Tamura et al., Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion, vol.8, p.793800, 2002.

M. Dosset, T. R. Vargas, A. Lagrange, R. Boidot, F. Végran et al., « PD-1/PD-L1 Pathway: An Adaptive Immune Resistance Mechanism to Immunogenic Chemotherapy in Colorectal Cancer, OncoImmunology, vol.7, issue.6, p.1433981, 2018.

S. Du, N. Mccall, K. Park, Q. Guan, P. Fontina et al., « Blockade of Tumor-Expressed PD-1 Promotes Lung Cancer Growth, Oncoimmunology, vol.7, issue.4, 2018.

R. Dummer, P. A. Ascierto, H. J. Gogas, A. Arance, M. Mandala et al., « Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS): A Multicentre, OpenLabel, Randomised Phase 3 Trial, The Lancet Oncology, vol.19, issue.5, pp.30142-30148, 2018.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, « Cancer Immunoediting: From Immunosurveillance to Tumor Escape », Nature Immunology, vol.3, issue.11, p.99198, 2002.

G. P. Dunn, J. Lloyd, R. D. Old, and . Schreiber, « The Three Es of Cancer Immunoediting, Annual Review of Immunology, vol.22, issue.1, p.32960, 2004.

. Edin, M. L. Sofia, A. M. Wikberg, J. Dahlin, and . Rutegård, Åke Öberg, Per-Arne Oldenborg, et Richard Palmqvist. 2012. « The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer, PLOS ONE, vol.7, issue.10, p.47045

A. Elia, S. Rita, . Caputo, M. Et, and . Bellone, « Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma, Frontiers in Immunology, vol.9, 2018.

H. K. Eltzschig, V. Michail, S. C. Sitkovsky, and . Robson, Purinergic Signaling during Inflammation, vol.367, p.232233, 2012.

A. M. Ercolini, H. Brian, E. A. Ladle, L. W. Manning, . Pfannenstiel et al.,

J. Armstrong, H. Machiels, J. G. Bieler, L. A. Emens, and R. T. Reilly,

E. M. Jaffee, Recruitment of Latent Pools of High-Avidity CD8(+) T Cells to the Antitumor Immune Response, vol.201, p.15911602, 2005.

. Erdag, J. T. Gulsun, M. E. Schaefer, D. H. Smolkin, S. M. Deacon et al., « Immunotype and Immunohistologic Characteristics of Tumor Infiltrating Immune Cells are Associated with Clinical Outcome in Metastatic Melanoma, Cancer Research, vol.72, issue.5, p.107080, 2012.

L. E. Estlack, C. C. Roth, G. L. Thompson, W. A. Lambert, and B. L. Ibey,

, « Nanosecond Pulsed Electric Fields Modulate the Expression of Fas/CD95 Death Receptor Pathway Regulators in U937 and Jurkat Cells, vol.19, p.175568

D. Fang, J. Hallman, N. Sangha, T. E. Kute, J. A. Hammarback et al.,

, « Expression of Microtubule-Associated Protein 2 in Benign and Malignant Melanocytes: Implications for Differentiation and Progression of Cutaneous Melanoma, vol.158, pp.64682-64684

L. Festino, V. Vanella, C. Trojaniello, P. A. Et, and . Ascierto, « Selecting Immuno-Oncology-Based Drug Combinations-What Should We Be Considering? » Expert Review of Clinical Pharmacology, septembre, vol.115, 2018.

I. J. Fidler, « Biological Behavior of Malignant Melanoma Cells Correlated to Their Survival in Vivo, Cancer Research, vol.35, issue.1, p.21824, 1975.

F. Foerster, S. Boegel, R. Heck, G. Pickert, N. Rüssel et al., « Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells, OncoImmunology, vol.7, issue.4, 2018.

K. A. Foon, « Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody, The New England Journal of Medicine, vol.307, issue.11, p.68687, 1982.

G. Forte, R. Sorrentino, A. Montinaro, A. Luciano, I. M. Adcock et al., « Inhibition of CD73 Improves B Cell-Mediated Anti-Tumor Immunity in a Mouse Model of Melanoma », Journal of Immunology, vol.189, issue.5, p.222633, 1950.

J. Fourcade, Z. Sun, M. Benallaoua, P. Guillaume, and F. Immanuel,

C. Luescher, J. M. Sander, V. Kirkwood, . Kuchroo, M. Et-hassane et al., , 2010.

, Upregulation of Tim-3 and PD-1 Expression Is Associated with Tumor Antigen-Specific CD8+

, Cell Dysfunction in Melanoma Patients ». The Journal of Experimental Medicine, vol.207, issue.10, p.217586

J. Fourcade, Z. Sun, O. Pagliano, J. Chauvin, C. Sander et al., « PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8 + T Cells Induced by Melanoma Vaccines », Cancer Research, vol.74, issue.4, 2014.

J. Fourcade, Z. Sun, O. Pagliano, P. Guillaume, I. F. Luescher et al., , 2012.

«. Cd8, Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1 », Cancer Research, vol.72, issue.4, p.88796

G. Frumento, R. Rotondo, M. Tonetti, and G. Damonte,

G. Ferrara, Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase », The Journal of Experimental Medicine, vol.196, issue.4, p.45968, 2002.

T. Fujimura, S. Ring, V. Umansky, K. Mahnke, and A. H. Enk, Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas, vol.132, p.123946, 2012.

D. Fukumura, K. Rakesh, and . Jain, « Imaging Angiogenesis and the Microenvironment ». APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica, vol.116, p.695715, 2008.

C. Gaggioli, S. Hooper, C. Hidalgo-carcedo, R. Grosse, J. F. Marshall et al., « Fibroblast-Led Collective Invasion of Carcinoma Cells with Differing Roles for RhoGTPases in Leading and Following Cells », Nature Cell Biology, vol.9, issue.12, p.13921400, 2007.

L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, and G. Kroemer, Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents, vol.28, p.690714, 2015.

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., « Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, 2006.

J. Galon, B. Mlecnik, G. Bindea, H. K. Angell, A. Berger et al., The Journal of Pathology, vol.232, issue.2, 199209.

T. C. Gangadhar, J. Bryan, T. M. Schneider, J. S. Bauer, A. I. Wasser et al., « Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO202/KEYNOTE-037, Journal of Clinical Oncology, vol.35, issue.15_suppl, p.90149014, 2017.

G. Garcin, F. Paul, M. Staufenbiel, Y. Bordat, J. Van-der-heyden et al., « High Efficiency Cell-Specific Targeting of Cytokine Activity », Nature Communications, vol.5, p.3016, 2014.

R. A. Gatti and R. A. Good, Occurrence of Malignancy in Immunodeficiency Diseases. A Literature Review, vol.28, p.8998, 1971.

F. Gerosa, B. Baldani-guerra, C. Nisii, V. Marchesini, and G. Carra,

G. Trinchieri, Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells, vol.195, p.32733, 2002.

G. Ghanem, J. Et, and . Fabrice, Tyrosinase Related Protein 1 (TYRP1/Gp75) in Human Cutaneous Melanoma, vol.5, p.15055, 2011.

F. Ghiringhelli and . Et-mélanie-bruchard, Les nouvelles combinaisons thérapeutiques, vol.3, p.17785, 2017.

F. Ghiringhelli, C. Menard, P. E. Puig, S. Ladoire, S. Roux et al., « Metronomic Cyclophosphamide Regimen Selectively Depletes CD4+CD25+ Regulatory T Cells and Restores T and NK Effector Functions in End Stage Cancer Patients, Cancer Immunology, Immunotherapy: CII, vol.56, issue.5, p.64148, 2007.

M. Giannakis, X. J. Mu, A. Sachet, . Shukla, O. Zhi-rong-qian et al., « Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma, Cell Reports, vol.15, issue.4, p.85765, 2016.

G. Johnson, R. M. Et, and H. Dong, B7-H1) by Immune Cells and Tumor Cells, vol.1, p.961, 2017.

H. J. Gogas, M. John, V. K. Kirkwood, and . Sondak, « Chemotherapy for Metastatic Melanoma: Time for a Change?, Cancer, vol.109, issue.3, p.45564, 2007.

E. B. Golden, S. Demaria, P. B. Schiff, A. Chachoua, C. Silvia et al., « An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer, Cancer Immunology Research, vol.1, issue.6, p.36572, 2013.

F. Gomes, F. Gueths, and . Nedel,

S. Tarquinio, « Tumor Angiogenesis and Lymphangiogenesis: Tumor/Endothelial Crosstalk and Cellular/Microenvironmental Signaling Mechanisms, Life Sciences, vol.92, issue.2, p.1017, 2013.

L. S. Goodman, M. Maxwell, W. Wintrobe, M. J. Dameshek, A. Goodman et al., « Nitrogen Mustard Therapy: Use of Methyl-Bis(BetaChloroethyl)Amine Hydrochloride and Tris(Beta-Chloroethyl)Amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders, JAMA, vol.251, issue.17, p.225561, 1984.

S. R. Gordon, L. Roy, B. W. Maute, G. Dulken, B. M. Hutter et al., PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity, vol.545, p.49599, 2017.

R. Govindan, A. Szczesna, M. Ahn, C. Schneider, P. F. Gonzalez-mella et al., « Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.35, issue.30, p.344957, 2017.

C. Granier, C. Dariane, P. Combe, V. Verkarre, S. Urien et al., « Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma ». Cancer Research, janvier, canres.0274, 2016.

K. D. Griffith, E. J. Read, J. A. Carrasquillo, C. S. Carter, J. C. Yang et al., « In Vivo Distribution of Adoptively Transferred Indium-111-Labeled Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Patients with Metastatic Melanoma, Journal of the National Cancer Institute, vol.81, issue.22, p.170917, 1989.

A. M. Grimaldi, E. Simeone, D. Giannarelli, P. Muto, S. Falivene et al., « Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy, OncoImmunology, vol.3, issue.5, p.28780, 2014.

L. Gros, H. Dreja, A. L. Fiser, M. Plays, M. Pelegrin et al., « Induction of Long-Term Protective Antiviral Endogenous Immune Response by Short Neutralizing Monoclonal Antibody Treatment, Journal of Virology, vol.79, issue.10, p.627280, 2005.

L. Gros, M. Pelegrin, H. Michaud, S. Bianco, J. Hernandez et al., « Endogenous Cytotoxic T-Cell Response Contributes to the Long-Term Antiretroviral Protection Induced by a Short Period of Antibody-Based Immunotherapy of Neonatally Infected Mice, Journal of Virology, vol.82, issue.3, p.1339, 2008.

,

J. F. Grosso, C. Cristin, T. J. Kelleher, C. H. Harris, E. L. Maris et al., « LAG-3 Regulates CD8+ T Cell Accumulation and Effector Function in Murine Self-and Tumor-Tolerance Systems, The Journal of Clinical Investigation, vol.117, issue.11, p.338392, 2007.

E. Guillebon, E. E. De, and . Tartour, « Immunité antitumorale (mécanismes, <Emphasis Type="Italic">immunoediting</Emphasis>, immunosurveillance), Oncologie, vol.17, issue.9, p.33744, 2015.

J. Haeuw, V. Caussanel, A. Et, and . Beck, « Les immunoconjugués, anticorps « armés » pour combattre le cancer ». médecine/sciences, vol.25, p.104652, 2009.

N. Halama, S. Michel, M. Kloor, I. Zoernig, A. Benner et al., « Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy, Cancer Research, vol.71, issue.17, p.567077, 2011.

O. Hamid, T. M. Bauer, A. I. Spira, D. C. Smith, A. J. Olszanski et al., « Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO202/KEYNOTE-037, Journal of Clinical Oncology, vol.35, issue.15_suppl, p.30123012, 2017.

S. Häusler, . Fm, . Itsaso-montalbán-del, J. Barrio, R. G. Diessner et al., « Anti-CD39 and Anti-CD73 Antibodies A1 and 7G2 Improve Targeted Therapy in Ovarian Cancer by Blocking Adenosine-Dependent Immune Evasion, American Journal of Translational Research, vol.6, issue.2, 2014.

Y. He, S. Liu, J. Mattei, P. A. Bunn, C. Zhou et al., « The Combination of Anti-KIR Monoclonal Antibodies with Anti-PD-1/PD-L1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC ». Drug Design, Development and Therapy, vol.12, p.98186, 2018.

J. P. Hebb, A. R. Mosley, F. Vences-catalán, N. Rajasekaran, A. Rosén et al., « Administration of Low-Dose Combination Anti-CTLA4, Anti-CD137, and Anti-OX40 into Murine Tumor or Proximal to the Tumor Draining Lymph Node Induces Systemic Tumor Regression, Cancer Immunology, Immunotherapy, vol.67, issue.1, p.4760, 2018.

S. R. Hingorani, L. Zheng, A. J. Bullock, T. E. Seery, W. P. Harris et al.,

F. Sigal and . Braiteh, « HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma, Journal of Clinical Oncology, vol.36, issue.4, p.35966, 2018.

S. M. Hiniker, A. Sunil, . Reddy, T. Holden, P. B. Maecker et al., « A Prospective Clinical Trial Combining Radiation Therapy with Systemic Immunotherapy in Metastatic Melanoma, International journal of radiation oncology, vol.96, issue.3, p.578, 2016.

,

F. Hodi, S. J. Stephen, D. F. O&apos;day, R. W. Mcdermott, J. A. Weber et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, vol.363, p.71123, 2010.

A. Holtzhausen, F. Zhao, K. Evans, M. Tsutsui, C. Orabona et al.,

E. Tyler, A. Brent, and . Hanks, « Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy ». Cancer Immunology Research, juin, canimm.0167, 2014.

D. W. Hoskin, J. S. Mader, S. J. Furlong, D. M. Conrad, and J. Blay,

, « Inhibition of T Cell and Natural Killer Cell Function by Adenosine and Its Contribution to Immune Evasion by Tumor Cells (Review), International Journal of Oncology, vol.32, issue.3, p.527

C. Huang, C. J. Workman, D. Flies, X. Pan, A. L. Marson et al., Role of LAG-3 in Regulatory T Cells, vol.21, p.503, 2004.

,

B. Huard, P. Gaulard, F. Faure, T. Hercend, and E. F. Triebel, « Cellular Expression and Tissue Distribution of the Human LAG-3-Encoded Protein, an MHC Class II Ligand, Immunogenetics, vol.39, issue.3, p.21317, 1994.

B. Huard, P. Prigent, M. Tournier, D. Bruniquel, and E. F. Triebel, « CD4/Major Histocompatibility Complex Class II Interaction Analyzed with CD4-and Lymphocyte Activation Gene-3 (LAG-3)-Ig Fusion Proteins, European Journal of Immunology, vol.25, issue.9, p.271821, 1995.

H. I. Hurwitz, L. Fehrenbacher, J. D. Hainsworth, W. Heim, J. Berlin et al., « Bevacizumab in Combination with Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.23, issue.15, p.35028, 2005.

P. Hwu, M. X. Du, R. Lapointe, M. Do, M. W. Taylor et al., « Indoleamine 2,3Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation », Journal of Immunology, vol.164, issue.7, p.359699, 1950.

R. Iannone, L. Miele, P. Maiolino, A. Pinto, S. Et et al., « Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model, American Journal of Cancer Research, vol.4, issue.2, p.17281, 2014.

R. Ji, « Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis, Cancer Letters, vol.346, issue.1, p.616, 2014.

D. Jin, J. Fan, L. Wang, L. F. Thompson, A. Liu et al., et Bin Zhang. 2010. « CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression ». Cancer Research, février, pp.8-5472

S. Kanda, K. Goto, H. Shiraishi, E. Kubo, A. Tanaka et al., , 2016.

«. Safety, Efficacy of Nivolumab and Standard Chemotherapy Drug Combination in Patients with Advanced Non-Small-Cell Lung Cancer: A Four Arms Phase Ib Study, Annals of Oncology: Official Journal of the European Society for Medical Oncology, vol.27, issue.12, p.224250

D. H. Kaplan, V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet et al.,

, « Demonstration of an Interferon Gamma-Dependent Tumor Surveillance System in Immunocompetent Mice, Proceedings of the National Academy of Sciences of the United States of America, vol.95, p.755661

H. Kaplon and J. M. Reichert, « Antibodies to Watch in, MAbs, vol.10, issue.2, p.183203, 2018.

I. Kareva and P. Hahnfeldt, « The Emerging "Hallmarks" of Metabolic Reprogramming and Immune Evasion: Distinct or Linked? » Cancer Research, février, canres.3696, 2012.

C. J. Karzmark and N. C. Pering, « Electron Linear Accelerators for Radiation Therapy: History, Principles and Contemporary Developments », Physics in Medicine and Biology, vol.18, issue.3, p.32154, 1973.

K. Kast, O. Schoffer, T. Link, A. Forberger, A. Petzold et al., « Trastuzumab and Survival of Patients with Metastatic Breast Cancer, vol.296, issue.2, p.30312, 2017.

H. Kawakami, I. Okamoto, K. Yonesaka, K. Okamoto, K. Shibata et al., « The Anti-HER3 Antibody Patritumab Abrogates Cetuximab Resistance Mediated by Heregulin in Colorectal Cancer Cells, Oncotarget, vol.5, issue.23, p.1184756, 2014.

D. N. Khalil, A. Michael, N. Postow, D. L. Ibrahim, J. Ludwig et al., « An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma ». Clinical cancer research : an official journal of the American Association for, Cancer Research, vol.22, issue.21, p.520410, 2016.

J. E. Kim, A. Mira, A. Patel, E. S. Mangraviti, D. Kim et al., « Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas, Clinical Cancer Research, 2016.

J. M. Kirkwood, M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden et al.,

, « Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684, vol.14, p.717

M. Kisielow, J. Kisielow, G. Capoferri-sollami, and K. Karjalainen, « Expression of Lymphocyte Activation Gene 3 (LAG-3) on B Cells Is Induced by T Cells, European Journal of Immunology, vol.35, issue.7, p.208188, 2005.

S. Kleffel, C. Posch, S. R. Barthel, H. Mueller, C. Schlapbach et al., « Melanoma Cell-Intrinsic PD, issue.1, 2015.

, Receptor Functions Promote Tumor Growth, Cell, vol.162, issue.6, p.124256

K. Klocke, R. Holmdahl, K. Et, and . Wing, CTLA-4 Expressed by FOXP3+, 2017.

, Regulatory T Cells Prevents Inflammatory Tissue Attack and Not T-Cell Priming in Arthritis, vol.152, p.12537

C. M. Koebel, W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig et al., Adaptive Immunity Maintains Occult Cancer in an Equilibrium State, vol.450, p.9037, 2007.

A. Kolb, J. Kleeff, N. Arnold, N. A. Giese, T. Giese et al., et Helmut Friess. 2007. « Expression and Differential Signaling of Heregulins in Pancreatic Cancer Cells, International Journal of Cancer, vol.120, issue.3, p.51423

K. Koller, H. B. Michael, H. Mackley, G. Wagner, T. Talamo et al., « Overall survival in patients with metastatic melanoma treated with concurrent ipilimumab and radiotherapy, Journal of Clinical Oncology, vol.34, issue.15_suppl, p.30233023, 2016.

P. Kosza?ka, M. Go?u?ska, M. Stanis?awowski, A. Urban, G. Stasi?oj? et al., et Jacek Bigda. 2015. « CD73 on B16F10 Melanoma Cells in CD73-Deficient Mice Promotes Tumor Growth

, Macrophage Infiltration and Metastasis, vol.69, p.110

G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel, « Immunogenic Cell Death in Cancer Therapy, Annual Review of Immunology, vol.31, issue.1, p.5172, 2013.

D. V. Krysko, D. Abhishek, A. Garg, O. Kaczmarek, P. Krysko et al., « Immunogenic Cell Death and DAMPs in Cancer Therapy », Nature Reviews Cancer, vol.12, issue.12, p.86075, 2012.

B. M. Künzli, M. Bernlochner, S. Rath, S. Käser, E. Csizmadia et al., Impact of CD39 and Purinergic Signalling on the Growth and Metastasis of Colorectal Cancer, vol.7, p.23141, 2011.

B. H. Ladle, M. J. Phillips, C. Yu, and C. J. Gamper, 2017. « Immune Modulatory Effects of Chemotherapy Increase the Effectiveness of Anti-PD1 Immunotherapy in a Poorly Immunogenic Murine Model of Osteosarcoma, The Journal of Immunology, vol.198, issue.1, pp.204-219

C. J. Langer, M. Shirish, H. Gadgeel, . Borghaei, A. Vassiliki et al., « Carboplatin and Pemetrexed with or without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study, The Lancet. Oncology, vol.17, issue.11, pp.30498-30501, 2016.

L. L. Lanier, Up on the Tightrope: Natural Killer Cell Activation and Inhibition, vol.9, p.495502, 2008.

A. Lapeyre-prost, M. Terme, S. Pernot, A. Pointet, T. Voron et al., « Chapter Seven-Immunomodulatory Activity of VEGF in Cancer, International Review of Cell and Molecular Biology, édité par Lorenzo Galluzzi, vol.330, p.295342, 2017.

Y. Latchman, C. R. Wood, T. Chernova, D. Chaudhary, M. Borde et al.,

«. Pd, L2 Is a Second Ligand for PD-1 and Inhibits T Cell Activation », Nature Immunology, vol.2, issue.3, p.26168

P. P. Lee, C. Yee, P. A. Savage, L. Fong, D. Brockstedt et al.,

D. Weber and . Johnson, « Characterization of Circulating T Cells Specific for Tumor-Associated Antigens in Melanoma Patients », Nature Medicine, vol.5, issue.6, p.67785, 1999.

S. M. Lee, D. C. Betticher, and E. N. Thatcher, « Melanoma: Chemotherapy ». British Medical Bulletin, vol.51, issue.3, p.60930, 1995.

A. Legat, H. Maby-el-hajjami, P. Baumgaertner, L. Cagnon, A. Samia et al., « Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients-Report of a Phase I/IIa Clinical Trial, Clinical Cancer Research, vol.22, issue.6, p.133040, 2016.

A. Levy, C. Massard, J. Soria, and E. Deutsch, « Concurrent Irradiation with the Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Blocker Durvalumab: Single Centre Subset Analysis from a Phase 1/2 Trial, European Journal of Cancer, vol.68, p.15662, 1990.

H. Li, X. Li, S. Liu, L. Guo, B. Zhang et al., « Programmed Cell Death-1 (PD-1) Checkpoint Blockade in Combination with a Mammalian Target of Rapamycin Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1 », Hepatology, vol.66, issue.6, p.192033, 2017.

. Li, J. L. Qingsheng, C. D. Harden, . Anderson, K. Nejat et al., « Tolerogenic Phenotype of IFN-?-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop, The Journal of Immunology, 2016.

. Lin, C. Chiou-feng, K. Lin, . Lee, . Szu-yuan et al., « Escape from IFN-?-dependent immunosurveillance in tumorigenesis, Journal of Biomedical Science, vol.24, 2017.

P. Lissoni, F. Malugani, A. Bonfanti, R. Bucovec, S. Secondino et al., « Abnormally Enhanced Blood Concentrations of Vascular Endothelial Growth Factor (VEGF) in Metastatic Cancer Patients and Their Relation to Circulating Dendritic Cells, IL-12 and Endothelin-1, Journal of Biological Regulators and Homeostatic Agents, vol.15, issue.2, p.14044, 2001.

H. Liu, L. Liu, K. Liu, P. Bizargity, W. W. Hancock et al.,

, Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression », Journal of Immunology, vol.183, issue.2, p.102231, 1950.

S. Loi, A. Giobbie-hurder, A. Gombos, T. Bachelot, R. Hui et al.,

, « Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-Positive Advanced Breast Cancer : Results from the PANACEA Study

S. Loi, S. Pommey, B. Haibe-kains, P. A. Beavis, P. K. Darcy et al., « CD73 Promotes Anthracycline Resistance and Poor Prognosis in Triple Negative Breast Cancer, Proceedings of the National Academy of Sciences, vol.110, issue.27, p.1109196, 2013.

A. Lokshin, T. Raskovalova, X. Huang, L. C. Zacharia, E. K. Jackson et al., Adenosine-Mediated Inhibition of the Cytotoxic Activity and Cytokine Production by Activated Natural Killer Cells, vol.66, p.775865, 2006.

G. V. Long, R. Dummer, A. Ribas, I. Puzanov, A. Vanderwalde et al., « Efficacy analysis of MASTERKEY265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma, Journal of Clinical Oncology, vol.34, issue.15_suppl, pp.9568-9568, 2016.

M. T. Lotze, A. E. Chang, C. A. Seipp, C. Simpson, J. T. Vetto et al., « High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer: Responses, Treatment-Related Morbidity, and Histologic Findings, JAMA, vol.256, issue.22, p.311724, 1986.

B. Lu, L. Sun, X. Yan, Z. Ai, J. Et et al., « Intratumoral Chemotherapy with Paclitaxel Liposome Combined with Systemic Chemotherapy: A New Method of Neoadjuvant Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer », Medical Oncology, vol.32, issue.1, p.345, 2015.

A. A. Lugade, P. James, S. A. Moran, R. C. Gerber, J. G. Rose et al., « Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor », Journal of Immunology, vol.174, issue.12, p.751623, 1950.

Y. Lui and S. J. Davis, « LAG-3: A Very Singular Immune Checkpoint », Nature Immunology, vol.19, issue.12, p.1278, 2018.

M. E. Lutsiak, R. T. Christine, R. D. Semnani, . Pascalis, V. S. Syed et al., « Inhibition of CD4(+)25+ T Regulatory Cell Function Implicated in Enhanced Immune Response by Low-Dose Cyclophosphamide, Blood, vol.105, issue.7, p.286268, 2005.

L. V. Ly, M. Sluijter, H. Sjoerd, M. J. Van-der-burg, . Jager et al.,

, Effective Cooperation of Monoclonal Antibody and Peptide Vaccine for the Treatment of Mouse Melanoma, The Journal of Immunology, vol.190, issue.1, p.48996

T. J. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi et al., « Ipilimumab in Combination with Paclitaxel and Carboplatin as First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results from a Randomized, Double-Blind, Multicenter Phase II Study, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.30, issue.17, p.204654, 2012.

. Maçon-lemaître, . Laëtitia, F. Et, and . Triebel, The Negative Regulatory Function of the Lymphocyte-Activation Gene-3 Co-Receptor (CD223) on Human T Cells, vol.115, p.17078, 2005.

. Malik, P. I. Ruchi, E. Lelkes, and . Cukierman, « Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer, Trends in Biotechnology, vol.33, issue.4, p.230, 2015.

,

M. Mandai, J. Hamanishi, K. Abiko, N. Matsumura, T. Baba et al., « Dual Faces of IFN-? in Cancer Progression: A Role of PD-L1 Induction in the Determination of pro-and Anti-Tumor Immunity ». Clinical Cancer Research, janvier, clincanres.0224, 2016.

J. Manzano, L. Luís, C. Layos, M. Bugés, L. De-los-llanos-gil et al., « Resistant mechanisms to BRAF inhibitors in melanoma, Annals of Translational Medicine, vol.4, issue.12, 2016.

,

V. Marmol and F. Beermann, « Tyrosinase and Related Proteins in Mammalian Pigmentation, FEBS Letters, vol.381, issue.3, p.16568, 1996.

G. Mathé, J. L. Amiel, L. Schwarzenberg, M. Schneider, A. Cattan et al., Active Immunotherapy for Acute Lymphoblastic Leukaemia, vol.1, p.69799, 1969.

J. Matsuzaki, S. Gnjatic, P. Mhawech-fauceglia, A. Beck, A. Miller et al., « Tumor-Infiltrating NY-ESO-1-Specific CD8+ T Cells Are Negatively Regulated by LAG-3 and PD-1 in Human Ovarian Cancer, Proceedings of the National Academy of Sciences of the United States of America, vol.107, p.787580, 2010.

J. P. Medema, J. De-jong, L. T. Peltenburg, E. M. Verdegaal, A. Gorter et al.,

. Franken, « Blockade of the Granzyme B/Perforin Pathway through Overexpression of the Serine Protease Inhibitor PI-9/SPI-6 Constitutes a Mechanism for Immune Escape by Tumors, Proceedings of the National Academy of Sciences of the United States of America, vol.98, p.1151520, 1920.

A. L. Mellor, D. H. Et, and . Munn, « Ido Expression by Dendritic Cells: Tolerance and Tryptophan Catabolism », Nature Reviews Immunology, vol.4, issue.10, p.76274, 2004.

P. Merwe, D. L. Anton-van-der, S. Bodian, P. Daenke, S. J. Linsley et al.,

«. Cd80, B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics, vol.185, p.393404

D. S. Micalizzi, M. Susan, . Farabaugh, L. Et-heide, and . Ford, « Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression, Journal of Mammary Gland Biology and Neoplasia, vol.15, issue.2, p.11734, 2010.

H. Michaud, J. Eliaou, and V. Lafont,

L. Gros, « Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity, Oncoimmunology, vol.3, issue.9, 2014.

H. Michaud, T. Gomard, L. Gros, K. Thiolon, R. Nasser et al., et Mireia Pelegrin. 2010. « A Crucial Role for Infected-Cell/Antibody Immune Complexes in the Enhancement of Endogenous Antiviral Immunity by Short Passive Immunotherapy, vol.6

,

M. Mingari, G. Cristina, L. Pietra, and . Moretta, « Human Cytolytic T Lymphocytes Expressing HLA Class-I-Specific Inhibitory Receptors, Current Opinion in Immunology, vol.17, issue.3, p.31219, 2005.

D. R. Minor, I. Puzanov, M. K. Callahan, and B. A. Hug, et Axel Hoos. 2015. « Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab, vol.28, p.61112

D. Mittal, A. Young, K. Stannard, M. Yong, M. W. Teng et al., Antimetastatic Effects of Blocking PD1 and the Adenosine A2A Receptor, 2014.

M. Q. Mohammed, S. Et, and . Retsas, « Oxaliplatin Is Active in Vitro against Human Melanoma Cell Lines: Comparison with Cisplatin and Carboplatin, Anti-Cancer Drugs, vol.11, issue.10, p.85963, 2000.

G. Mondanelli, S. Ugel, U. Grohmann, V. Et, and . Bronte, « The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO ». Current Opinion in Pharmacology, ? Cancer ? Tribute to Norman Bowery, vol.35, p.3039, 2017.

. Monney, C. A. Laurent, J. L. Sabatos, A. Gaglia, H. Ryu et al., Th1-Specific Cell Surface Protein Tim-3, 2002.

, Regulates Macrophage Activation and Severity of an Autoimmune Disease, Nature, vol.415, issue.6871, p.53641

I. Monteiro, S. Vigano, M. Faouzi, I. Treilleux, O. Michielin et al., « CD73 expression and clinical significance in human metastatic melanoma, Oncotarget, vol.9, issue.42, p.2665969, 2018.

S. Morello, M. Capone, C. Sorrentino, D. Giannarelli, G. Madonna et al.,

, « Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab, Journal of Translational Medicine, vol.15

,

K. D. Moynihan, F. Cary, G. L. Opel, A. Szeto, E. F. Tzeng et al.,

R. T. Engreitz and . Williams, « Eradication of Large Established Tumors in Mice by Combination Immunotherapy That Engages Innate and Adaptive Immune Responses », Nature Medicine, vol.22, issue.12, p.140210, 2016.

D. H. Munn, A. L. Et, and . Mellor, « Indoleamine 2,3 dioxygenase and metabolic control of immune responses, Trends in immunology, vol.34, issue.3, p.13743, 2013.

R. Nasser, M. Pelegrin, H. Michaud, M. Plays, M. Piechaczyk et al., « Long-Lasting Protective Antiviral Immunity Induced by Passive Immunotherapies Requires both Neutralizing and Effector Functions of the Administered Monoclonal Antibody, Journal of Virology, vol.84, p.1016981, 2010.

R. Nasser, M. Pelegrin, M. Plays, L. Gros, and M. Piechaczyk, « Control of Regulatory T Cells Is Necessary for Vaccine-like Effects of Antiviral Immunotherapy by Monoclonal Antibodies, Blood, vol.121, issue.7, p.110211, 2013.

S. Ngiow, . Foong, H. Bianca-von-scheidt, H. Akiba, M. W. Yagita et al., Anti-TIM3 Antibody Promotes T Cell IFN-?-Mediated Antitumor Immunity and Suppresses Established Tumors, 2011.

C. J. Nirschl, C. G. Et, and . Drake, « Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.19, issue.18, p.491724, 2013.

M. Obeid, A. Tesniere, F. Ghiringhelli, G. M. Fimia, L. Apetoh et al., « Calreticulin Exposure Dictates the Immunogenicity of Cancer Cell Death », Nature Medicine, vol.13, issue.1, p.5461, 2007.

O. Donnell, J. S. , G. V. Long, R. A. Scolyer, M. W. Teng et al., Resistance to PD1/PDL1 Checkpoint Inhibition, vol.52, p.7181, 2017.

C. Ogier, P. Colombo, C. Bousquet, L. Canterel-thouennon, P. Sicard et al., Targeting the NRG1/HER3 Pathway in Tumor Cells and Cancer-Associated Fibroblasts with an Anti-Neuregulin 1, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01822771

, Antibody Inhibits Tumor Growth in Pre-Clinical Models of Pancreatic Cancer », Cancer Letters, vol.432, p.22736

A. Ohta, E. Gorelik, S. J. Prasad, F. Ronchese, D. Lukashev et al.,

K. Wong and X. Huang, « A2A Adenosine Receptor Protects Tumors from Antitumor T Cells, Proceedings of the National Academy of Sciences, vol.103, p.1313237, 2006.

A. Ohta and M. Sitkovsky, « Extracellular Adenosine-Mediated Modulation of Regulatory T Cells », Frontiers in Immunology, vol.5, p.304, 2014.

C. Olivares and F. Solano, « New Insights into the Active Site Structure and Catalytic Mechanism of Tyrosinase and Its Related Proteins, Pigment Cell & Melanoma Research, vol.22, issue.6, p.75060, 2009.

B. C. Özdemir, T. Pentcheva-hoang, J. L. Carstens, X. Zheng, C. Wu et al., « Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Diminished Survival, Cancer cell, vol.25, issue.6, p.71934, 2014.

D. M. Pardoll, « The Blockade of Immune Checkpoints in Cancer Immunotherapy », Nature Reviews Cancer, vol.12, issue.4, p.25264, 2012.

J. Park, R. Omiya, Y. Matsumura, Y. Sakoda, A. Kuramasu et al., « B7-H1/CD80 Interaction Is Required for the Induction and Maintenance of Peripheral T Cell Tolerance ». Blood, janvier, 2010.

S. Park, Z. Jiang, E. D. Mortenson, L. Deng, O. Radkevich-brown et al., The Therapeutic Effect of Anti-HER2/Neu Antibody Depends on Both Innate and Adaptive Immunity », vol.18, p.16070, 2010.

R. V. Parry, J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, . Braunstein et al.,

, « CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms, vol.25, p.954353, 2005.

A. Passarelli, F. Mannavola, S. Luigia, M. Stucci, and . Tucci, et Francesco Silvestris. 2017. « Immune system and melanoma biology: a balance between immunosurveillance and immune escape, vol.8, p.10613242

D. Patel, R. Bassi, A. T. Hooper, H. Sun, J. Huber et al., « Enhanced Suppression of Melanoma Tumor Growth and Metastasis by Combined Therapy with Anti-VEGF Receptor and Anti-TYRP-1/Gp75 Monoclonal Antibodies, Anticancer Research, vol.28, issue.5A, p.267986, 2008.

L. Paz-ares, J. Brahmer, M. D. Hellmann, M. Reck, K. O&apos;byrne et al., « 144TiPCheckMate 227: A Randomized, OpenLabel Phase 3 Trial of Nivolumab, Nivolumab plus Ipilimumab, or Nivolumab plus Chemotherapy versus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NonSmall Cell Lung Cancer (NSCLC), Annals of Oncology, vol.28, 2017.

,

A. Pearce, M. Haas, R. Viney, S. Pearson, P. Haywood et al., « Incidence and Severity of Self-Reported Chemotherapy Side Effects in Routine Care: A Prospective Cohort Study », PLOS ONE, vol.12, issue.10, p.184360, 2017.

I. Penn, « Primary Kidney Tumors before and after Renal Transplantation, » Transplantation, vol.59, issue.4, p.48085, 1995.

A. Petrizzo, A. Mauriello, A. Luciano, D. Rea, A. Barbieri et al., « Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting, Oncotarget, vol.9, issue.3, p.357689, 2017.

S. Piconese, B. Valzasina, M. P. Et, and . Colombo, « OX40 Triggering Blocks Suppression by Regulatory T Cells and Facilitates Tumor Rejection, The Journal of Experimental Medicine, vol.205, issue.4, p.82539, 2008.

J. M. Pitt, M. Vétizou, R. Daillère, P. María, T. Roberti et al., « Resistance Mechanisms to ImmuneCheckpoint Blockade in Cancer: Tumor-Intrinsic and-Extrinsic Factors, Immunity, vol.44, issue.6, p.125569, 2016.

M. A. Postow, K. Margaret, C. A. Callahan, Y. Barker, J. Yamada et al., Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma, vol.366, p.92531, 2012.

M. A. Postow, K. Margaret, J. D. Callahan, and . Wolchok, « Immune Checkpoint Blockade in Cancer Therapy, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.33, issue.17, p.197482, 2015.

. Practitioners, The Royal Australian College of General. s. d. « RACGP-Immunotherapy of

, Consulté le 22 juin 2018

. Prasanna, M. M. Anish, M. Ahmed, C. Mohiuddin, and . Norman-coleman, « Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy, Journal of Thoracic Disease, vol.6, issue.4, p.287302, 2014.

D. Puyraimond-zemmour, S. Et, and . Vignot, Le métabolisme de la cellule tumorale : l'effet Warburg, vol.15, p.43540, 2013.

. Puzanov, M. M. Igor, D. Milhem, O. Minor, A. Hamid et al., Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma, vol.34, p.261926, 2016.

G. Qian, N. Jiang, D. Wang, S. Newman, S. Kim et al., Heregulin and HER3 Are Prognostic Biomarkers in Oropharyngeal Squamous Cell Carcinoma, vol.121, p.36003611, 1920.

O. S. Qureshi, Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti et al.,

J. Schmidt and . Baker, « Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4, Science, vol.332, issue.6029, p.600603, 2011.

M. Rajabi, A. Shaker, and . Mousa, « The Role of Angiogenesis in Cancer Treatment, Biomedicines, vol.5, issue.2, p.34, 2017.

M. Rangachari, C. Zhu, K. Sakuishi, S. Xiao, J. Karman et al., « Bat3 Promotes T Cell Responses and Autoimmunity by Repressing Tim-3-Mediated Cell Death and Exhaustion », Nature Medicine, vol.18, issue.9, pp.1394-1400, 2012.

H. S. Raper, « The Tyrosinase-Tyrosine Reaction: Production from Tyrosine of 5: 6Dihydroxyindole and 5: 6-Dihydroxyindole-2-Carboxylic Acid-the Precursors of Melanin, The Biochemical Journal, vol.21, issue.1, p.8996, 1927.

M. Reck, A. Luft, A. Szczesna, L. Havel, S. Kim et al., « Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.34, issue.31, p.374048, 2016.

W. L. Redmond, J. Michael, B. Gough, T. L. Charbonneau, A. D. Ratliff et al., « Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist », Journal of Immunology, vol.179, issue.11, p.724453, 1950.

W. L. Redmond, N. Stefanie, M. J. Linch, and . Kasiewicz, « Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity, Cancer Immunology Research, vol.2, issue.2, p.142, 2014.

,

W. L. Redmond, C. E. Ruby, and A. D. Weinberg, « The Role of OX40Mediated Co-Stimulation in T-Cell Activation and Survival, Critical Reviews in Immunology, vol.29, issue.3, p.187201, 2009.

N. P. Restifo, J. Mark, A. Smyth, and . Snyder, « Acquired Resistance to Immunotherapy and Future Challenges », Nature Reviews. Cancer, vol.16, issue.2, p.12126, 2016.

A. Ribas, M. Butler, J. Lutzky, D. P. Lawrence, C. Robert et al., « Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma, Journal of Clinical Oncology, vol.33, issue.15_suppl, p.30033003, 2015.

A. Ribas, F. Stephen-hodi, M. Callahan, and C. Konto, et Jedd Wolchok. 2013. « Hepatotoxicity with Combination of Vemurafenib and Ipilimumab, vol.368, p.136566

A. Ribas, R. Kefford, M. A. Marshall, J. A. Cornelis, J. B. Punt et al., « Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma », Journal of Clinical Oncology, vol.31, issue.5, p.61622, 2013.

D. Ribatti, E. Crivellato, and E. A. Vacca, 2012. « Inflammation and Antiangiogenesis in Cancer

D. Ribatti, « The Concept of Immune Surveillance against Tumors: The First Theories, Oncotarget, vol.8, issue.4, 2017.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., « Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial, Lancet, vol.389, p.25565, 2017.

N. A. Rizvi, D. Matthew, J. R. Hellmann, R. A. Brahmer, H. Juergens et al., « Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer », Journal of Clinical Oncology, vol.34, issue.25, p.296979, 2016.

C. Robert, J. Schachter, G. V. Long, A. Arance, J. J. Grob et al., Pembrolizumab versus Ipilimumab in Advanced Melanoma, vol.372, p.252132, 2015.

C. Robert, L. Thomas, I. Bondarenko, O. Steven, J. Day et al., Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, vol.364, p.251726, 2011.

J. Robert, « Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread, vol.11, p.33, 2016.

A. Roger, A. Finet, B. Boru, A. Beauchet, J. Mazeron et al., « Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients, OncoImmunology, vol.7, issue.7, p.1442166, 2018.

P. R. Rogers, J. Song, I. Gramaglia, N. Killeen, and M. Croft, « OX40 Promotes Bcl-xL and Bcl-2 Expression and Is Essential for Long-Term Survival of CD4 T Cells, Immunity, vol.15, issue.3, pp.191-192, 2001.

S. A. Rosenberg, J. Lotze, W. Yang, C. M-linehan, . Seipp et al., « Combination therapy with interleukin-2 and alphainterferon for the treatment of patients with advanced cancer, Journal of Clinical Oncology, vol.7, issue.12, p.186374, 1989.

S. A. Rosenberg, « IL-2: The First Effective Immunotherapy for Human Cancer », Journal of Immunology, vol.192, issue.12, p.545158, 1950.

S. A. Rosenberg, C. James, R. M. Yang, U. S. Sherry, and M. S. Kammula,

G. Q. Hughes, D. E. Phan, and . Citrin, « Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy ». Clinical cancer research : an official journal of the American Association for, Cancer Research, vol.17, issue.13, p.455057, 2011.

J. Rossowska, N. Anger, A. Szczygie?, J. Mierzejewska, and . Et-el?bieta-pajtasz-piasecka, « Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy, Journal of Experimental & Clinical Cancer Research, vol.37, p.126, 2018.

W. Roth and J. C. Reed, « FLIP Protein and TRAIL-Induced Apoptosis, Vitamins and Hormones, vol.67, pp.67011-67018, 2004.

C. E. Rudd, A. Taylor, and H. Schneider, « CD28 and CTLA-4 coreceptor expression and signal transduction, Immunological reviews, vol.229, issue.1, p.1226, 2009.

B. Ruffell and L. M. Coussens, « Macrophages and Therapeutic Resistance in Cancer, Cancer Cell, vol.27, issue.4, p.46272, 2015.

R. Ryu and K. E. Ward, « Atezolizumab for the First-Line Treatment of NonSmall Cell Lung Cancer (NSCLC): Current Status and Future Prospects », Frontiers in Oncology, vol.8, 2018.

R. Sadej and A. C. Skladanowski, Enzymatic and Non-Enzymatic, Function of Ecto-5'-Nucleotidase (EN, CD73) in Migration and Invasion of A375 Melanoma Cells, Dual, vol.59, p.64752, 2012.

R. Sadej, J. Spychala, C. Et-andrzej, and . Skladanowski, « Expression of Ecto-5'Nucleotidase (EN, CD73) in Cell Lines from Various Stages of Human Melanoma, Melanoma Research, vol.16, issue.3, p.21322, 2006.

C. P. Saris, P. J. Van-de-vaart, R. C. Rietbroek, and F. A. Blommaert, « In Vitro Formation of DNA Adducts by Cisplatin, Lobaplatin and Oxaliplatin in Calf Thymus DNA in Solution and in Cultured Human Cells, Carcinogenesis, vol.17, issue.12, p.276369, 1996.

S. Satoshi, H. Yoshino, K. Miyamoto, M. Yonemori, T. Sakaguchi et al., « 457-Targeting HRAS as a potential therapeutic target through RAS inhibitor salirasib in bladder cancer, Abstracts EAU1833rd Annual EAU Congress, vol.17, pp.31294-31300, 2018.

P. J. Schuler, Z. Saze, C. Hong, L. Muller, D. G. Gillespie et al., « Human CD4+ CD39+ Regulatory T Cells Produce Adenosine upon Co-Expression of Surface CD73 or Contact with CD73+ Exosomes or CD73+ Cells, Clinical and Experimental Immunology, vol.177, issue.2, p.53143, 2014.

B. Seliger, U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber, « Characterization of the Major Histocompatibility Complex Class I Deficiencies in B16 Melanoma Cells, Cancer Research, vol.61, issue.3, p.109599, 2001.

T. Seremet, S. Planken, J. K. Schwarze, Y. Jansen, and L. Vandeweerd, Robbe van den Begin, Ioannis Tsechelidis, Danielle Lienard, Véronique Del Marmol, et Bart Neyns. 2018. « Successful Treatment with Intralesional Talimogene Laherparepvec in Two Patients with Immune Checkpoint Inhibitors Refractory Advanced Melanoma

. Serra, A. L. Sara, T. Horenstein, D. Vaisitti, D. Brusa et al., « CD73-Generated Extracellular Adenosine in Chronic Lymphocytic Leukemia Creates Local Conditions Counteracting Drug-Induced Cell Death, Blood, vol.118, issue.23, p.614152, 2011.

V. Shankaran, H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson et al.,

«. Ifngamma, Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity », Nature, vol.410, issue.6832, p.110711

P. Sharma, S. Hu-lieskovan, and J. A. Wargo, et Antoni Ribas. 2017. « Primary, Adaptive, and Acquired Resistance, vol.168, p.707

,

E. Sharon, D. Van-dijk, Y. Kalma, L. Keren, O. Manor et al., « Probing the effect of promoters on noise in gene expression using thousands of designed sequences, Genome Research, vol.24, issue.10, p.16981706, 2014.

N. Shaverdian, A. E. Lisberg, K. Bornazyan, D. Veruttipong, J. W. Goldman et al., « Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, The Lancet. Oncology, vol.18, issue.7, pp.30380-30387, 2017.

J. W. Shay, Y. Zou, E. Hiyama, W. E. Et, and . Wright, Telomerase and Cancer, vol.10, p.67785, 2001.

M. Shibuya and L. Claesson-welsh, « Signal Transduction by VEGF Receptors in Regulation of Angiogenesis and Lymphangiogenesis, Experimental Cell Research, vol.312, issue.5, p.54960, 2006.

Y. Shinkai, K. Rathbun, E. M. Lam, V. Oltz, M. Stewart et al., « RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement », Cell, vol.68, issue.5, p.85567, 1992.

D. Sia, C. Alsinet, P. Newell, A. Et, and . Villanueva, « VEGF Signaling in Cancer Treatment, 2014.

A. Sica, T. Schioppa, A. Mantovani, P. Et, and . Allavena, « Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy, European Journal of Cancer, vol.42, issue.6, p.71727, 2006.

G. P. Sims, C. Daniel, S. T. Rowe, R. Rietdijk, . Herbst et al., , 2010.

«. Hmgb1, Annual Review of Immunology, vol.28, issue.1, p.36788

A. Sistigu, T. Yamazaki, E. Vacchelli, K. Chaba, D. P. Enot et al., « Cancer Cell-Autonomous Contribution of Type I Interferon Signaling to the Efficacy of Chemotherapy », Nature Medicine, vol.20, issue.11, p.13019, 2014.

M. V. Sitkovsky, S. Hatfield, R. Abbott, B. Belikoff, and D. Lukashev,

A. Ohta, « Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists, Cancer Immunology Research, vol.2, issue.7, p.598605, 2014.

D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich et al., Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER, 1987.

/. Neu-oncogene, Science, vol.235, issue.4785, p.17782

A. Slany, A. Bileck, B. Muqaku, and C. Gerner, « Targeting Breast Cancer-Associated Fibroblasts to Improve Anti-Cancer Therapy, Breast (Edinburgh, Scotland), vol.24, issue.5, p.53238, 2015.

S. F. Slovin, C. S. Higano, O. Hamid, S. Tejwani, A. Harzstark et al., « Ipilimumab Alone or in Combination with Radiotherapy in Metastatic CastrationResistant Prostate Cancer: Results from an Open-Label, Multicenter Phase I/II Study, Annals of Oncology: Official Journal of the European Society for Medical Oncology, vol.24, issue.7, p.181321, 2013.

M. J. Smyth, A. Shin-foong-ngiow, . Ribas, W. L. Et-michele, and . Teng, « Combination Cancer Immunotherapies Tailored to the Tumour Microenvironment », Nature Reviews. Clinical Oncology, vol.13, issue.3, p.14358, 2016.

M. J. Smyth, Y. T. Kevin, S. E. Thia, D. Street, D. I. Macgregor et al., « Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma », Journal of Experimental Medicine, vol.192, issue.5, p.75560, 2000.

J. T. Sockolosky, M. Dougan, J. R. Ingram, C. Chi, M. Ho et al.,

S. C. Kauke, H. L. Almo, K. C. Ploegh, and . Garcia, « Durable Antitumor Responses to CD47 Blockade Require Adaptive Immune Stimulation, Proceedings of the National Academy of Sciences of the United States of America, vol.113, pp.2646-2654, 2016.

. Somasundaram, D. Veena, G. Basudhar, J. H. Bharadwaj, L. A. No et al., « Molecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism, 2018.

R. Speeckaert, K. Vermaelen, P. Nanja-van-geel, J. Autier, M. Lambert et al., 3-Dioxygenase, a New Prognostic Marker in Sentinel Lymph Nodes of Melanoma Patients, European Journal of Cancer, vol.2, issue.13, 1990.

J. Stagg, P. A. Beavis, U. Divisekera, C. P. Mira, A. Liu et al., « CD73-Deficient Mice Are Resistant to Carcinogenesis. » Cancer Research, mars, 2012.

J. Stagg, U. Divisekera, H. Duret, T. Sparwasser, M. W. Teng et al.,

E. Darcy, J. Mark, and . Smyth, « CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis, 2011.

J. Stagg, U. Divisekera, N. Mclaughlin, J. Sharkey, S. Pommey et al., Anti-CD73 Antibody Therapy Inhibits Breast Tumor Growth and Metastasis, vol.107, p.154752, 2010.

O. Stutman, « Chemical Carcinogenesis in Nude Mice: Comparison between Nude Mice from Homozygous Matings and Heterozygous Matings and Effect of Age and Carcinogen Dose », Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice ». Science, vol.183, p.35358, 1974.

X. Sun, Y. Wu, W. Gao, K. Enjyoji, E. Csizmadia et al., « CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice, Gastroenterology, vol.139, issue.3, p.103040, 2010.

B. Sveinbjørnsson, A. Camilio, B. E. Haug, and . Et-Øystein-rekdal, « LTX315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment, Future Medicinal Chemistry, vol.9, issue.12, p.133944, 2017.

J. B. Swann, D. Matthew, A. Vesely, J. Silva, S. Sharkey et al., « Demonstration of Inflammation-Induced Cancer and Cancer Immunoediting during Primary Tumorigenesis, Proceedings of the National Academy of Sciences, vol.105, issue.2, p.65256, 2008.

M. A. Swartz, N. Iida, E. W. Roberts, S. Sangaletti, M. H. Wong et al., « Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy ». Cancer Research, mars, canres.0122, 2012.

T. Tadmor, Y. Zhang, H. Cho, E. R. Podack, and J. D. Rosenblatt, « The Absence of B Lymphocytes Reduces the Number and Function of T-Regulatory Cells and Enhances the Anti-Tumor Response in a Murine Tumor Model, Cancer Immunology, Immunotherapy: CII, vol.60, issue.5, p.60919, 2011.

T. Tai, M. Eisinger, S. Ogata, and K. O. Lloyd, Glycoproteins as Differentiation Markers in Human Malignant Melanoma and Melanocytes, vol.43, p.277379, 1983.

T. Tammela and K. A. , « Lymphangiogenesis: Molecular Mechanisms and Future Promise, Cell, vol.140, issue.4, p.46076, 2010.

C. Tang, J. W. Welsh, P. De-groot, E. Massarelli, J. Y. Chang et al., « Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells ». Clinical cancer research : an official journal of the American Association for, Cancer Research, vol.23, issue.6, p.138896, 2017.

D. Tang, J. Gao, S. Wang, N. Ye, Y. Chong et al., Cancer-Associated Fibroblasts Promote Angiogenesis in Gastric Cancer through Galectin-1 Expression, vol.37, p.188999, 2016.

L. Tao, G. Huang, H. Song, Y. Chen, L. Et et al., « Cancer associated fibroblasts: An essential role in the tumor microenvironment, Review) ». Oncology Letters, vol.14, issue.3, p.261120, 2017.

C. Taylor, D. Hershman, N. Shah, N. Suciu-foca, D. P. Petrylak et al., « Augmented HER-2-Specific Immunity during Treatment with Trastuzumab and Chemotherapy, Clinical Cancer Research, vol.13, issue.17, p.513343, 2007.

A. Tesniere, . Schlemmer, . Boige, . Kepp, . Martins et al., , 2010.

, « Immunogenic Death of Colon Cancer Cells Treated with Oxaliplatin, Oncogene, vol.29, issue.4, p.482

,

L. They, H. Michaud, O. Becquart, V. Lafont, B. Guillot et al., « PD-1 Blockade at the Time of Tumor Escape Potentiates the Immune-Mediated Antitumor Effects of a Melanoma-Targeting Monoclonal Antibody, Oncoimmunology, vol.6, issue.10, p.1353857, 2017.

J. F. Thompson, P. Hersey, E. Et, and . Wachter, « Chemoablation of Metastatic Melanoma Using Intralesional Rose Bengal », Melanoma Research, vol.18, issue.6, p.40511, 2008.

T. M. Thomson, M. J. Mattes, L. Roux, L. J. Old, and K. O. Lloyd, PigmentationAssociated Glycoprotein of Human Melanomas and Melanocytes: Definition with a Mouse Monoclonal Antibody, vol.85, p.16974, 1985.

J. J. Tomasek, G. Gabbiani, B. Hinz, C. Chaponnier, and R. A. Brown,

«. Myofibroblasts and . Mechano, Regulation of Connective Tissue Remodelling, vol.3, p.34963

S. L. Topalian, G. Charles, D. M. Drake, and . Pardoll, « Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, Cancer Cell, vol.27, issue.4, p.450, 2015.

,

S. L. Topalian, F. Stephen, J. R. Hodi, S. N. Brahmer, D. C. Gettinger et al., Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, vol.366, p.244354, 2012.

V. P. Torchilin, « Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example, Handbook of Experimental Pharmacology, vol.197, p.353, 2010.

F. Triebel, S. Jitsukawa, E. Baixeras, S. Roman-roman, C. Genevee et al., « LAG-3, a Novel Lymphocyte Activation Gene Closely Related to CD4, The Journal of Experimental Medicine, vol.171, issue.5, p.13931405, 1990.

C. L. Trimble, P. Matthew, K. A. Morrow, X. Kraynyak, M. Shen et al., « Safety, Efficacy, and Immunogenicity of VGX-3100, a Therapeutic Synthetic DNA Vaccine Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins for Cervical Intraepithelial Neoplasia 2/3: A Randomised, Double-Blind, PlaceboControlled Phase 2b Trial, Lancet, vol.386, pp.239-240, 2015.

. Tsai, L. A. Miaw-sheue, I. Shamon-taylor, C. K. Mehmi, R. Tang et al.,

, Blockage of Heregulin Expression Inhibits Tumorigenicity and Metastasis of Breast Cancer, Oncogene, vol.22, issue.5, p.76168

J. Tschopp, M. Irmler, and M. Thome, « Inhibition of Fas Death Signals by FLIPs, Current Opinion in Immunology, vol.10, issue.5, p.55258, 1998.

S. Y. Tseng, M. Otsuji, K. Gorski, X. Huang, J. E. Slansky et al., B7-DC, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells, vol.193, p.83946, 2001.

J. M. Tsui, C. Mihalcioiu, and . Cury, Consulté le 26 août, vol.10, 2018.

F. Tsushima, S. Yao, T. Shin, A. Flies, S. Flies et al., et Lieping Chen. 2007. « Interaction between B7-H1 and PD-1

, Determines Initiation and Reversal of T-Cell Anergy ». Blood, vol.110, issue.1, p.18085

M. Turcotte, D. Allard, D. Mittal, Y. Bareche, L. Buisseret et al., « CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy ». Cancer Research, janvier, 2017.

P. Uotila, « The Role of Cyclic AMP and Oxygen Intermediates in the Inhibition of Cellular Immunity in Cancer, Cancer Immunology, Immunotherapy: CII, vol.43, issue.1, p.19, 1996.

U. Uslu, M. Erdmann, S. Schliep, J. Dörrie, N. Schaft et al., « Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-Term Responding Patients with Metastatic Melanoma, Anticancer Research, vol.37, issue.6, p.324348, 2017.

E. Vacchelli, F. Aranda, N. Bloy, A. Buqué, I. Cremer et al., « Trial Watch-Immunostimulation with cytokines in cancer therapy, Oncoimmunology, vol.5, issue.2, 2015.

A. H. Veen, J. H. Van-der, A. M. De-wilt, S. T. Eggermont, A. L. Van-tiel et al., « TNF-Alpha Augments Intratumoural Concentrations of Doxorubicin in TNFAlpha-Based Isolated Limb Perfusion in Rat Sarcoma Models and Enhances Anti-Tumour Effects, British Journal of Cancer, vol.82, issue.4, p.97380, 2000.

M. D. Vesely, H. Michael, R. D. Kershaw, M. J. Schreiber, and . Smyth, Natural Innate and Adaptive Immunity to Cancer, vol.29, pp.235-71, 2011.

M. Vu, X. Diem, W. Xiao, N. Gao, M. Degauque et al., OX40 Costimulation Turns off Foxp3+ Tregs, vol.110, p.250110, 2007.

L. S. Walker, « Treg and CTLA-4: Two Intertwining Pathways to Immune Tolerance, Journal of Autoimmunity, vol.45, p.4957, 2013.

T. L. Walunas, J. Deborah, C. Y. Lenschow, P. S. Bakker, G. J. Linsley et al., « CTLA-4 can function as a negative regulator of T cell activation, Immunity, vol.1, issue.5, p.40513, 1994.

H. Wang, . Lee, . Lo-nigro, . Lattanzio, . Merlano et al., , 2012.

«. Nt5e, CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity, British Journal of Cancer, vol.106, issue.8, p.144652

L. Wang, K. Pino-lagos, C. Victor, I. De-vries, M. H. Guleria et al.,

R. J. Noelle, « Programmed Death 1 Ligand Signaling Regulates the Generation of Adaptive Foxp3+CD4+ Regulatory T Cells, Proceedings of the National Academy of Sciences of the United States of America, vol.105, p.933136, 2008.

L. Wang, J. Fan, L. F. Thompson, Y. Zhang, T. Shin et al.,

«. Has, Distinct Roles in Nonhematopoietic and Hematopoietic Cells to Promote Tumor Growth in Mice, The Journal of Clinical Investigation, vol.121, issue.6, p.237182

P. Waterhouse, J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian et al., , 1995.

, « Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4, vol.270, p.98588

J. S. Weber, P. Sandra, D. D&apos;angelo, F. Minor, R. Stephen-hodi et al., « Nivolumab versus Chemotherapy in Patients with Advanced Melanoma Who Progressed after Anti-CTLA-4 Treatment (CheckMate 037): A Randomised, Controlled, Open-Label, Phase 3 Trial, The Lancet. Oncology, vol.16, issue.4, pp.70076-70084, 2015.

B. Weide, D. Neri, G. Et, and . Elia, « Intralesional treatment of metastatic melanoma: a review of therapeutic options, Cancer immunology, immunotherapy : CII, vol.66, issue.5, p.64756, 2017.

N. R. West, K. Milne, P. T. Truong, N. Macpherson, B. H. Nelson et al., « Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer, Breast Cancer Research, vol.13, p.126, 2011.

T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton et al., « Widespread Potential for Growth-Factor-Driven Resistance to Anticancer Kinase Inhibitors », Nature, vol.487, issue.7408, p.5059, 2012.

K. Wing, Y. Onishi, P. Prieto-martin, T. Yamaguchi, M. Miyara et al., CTLA-4 Control over Foxp3+ Regulatory T Cell Function ». Science, vol.322, p.27175, 2008.

C. J. Workman, Y. Wang, K. C. El-kasmi, D. M. Pardoll, P. J. Murray et al., LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis, vol.182, p.188591, 2009.

J. M. Woynarowski, W. G. Chapman, C. Napier, M. C. Herzig, and E. P. Juniewicz, « Sequence-and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA », Molecular Pharmacology, vol.54, issue.5, p.77077, 1998.

A. A. Wu, V. Drake, H. Huang, and S. Chiu, et Lei Zheng. 2015. « Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells ». Oncoimmunology, vol.4

. Wu, X. Xian-rui, Y. He, R. Chen, Y. Yuan et al., « High Expression of CD73 as a Poor Prognostic Biomarker in Human Colorectal Cancer, Journal of Surgical Oncology, vol.106, issue.2, p.13037, 2012.

Y. Xu, X. Zhou, M. Mei, and Y. Ren, Reprograming Carcinoma Associated Fibroblasts by MicroRNAs, 2017.

,

T. Yamazaki, J. M. Pitt, M. Vétizou, A. Marabelle, C. Flores et al., « The Oncolytic Peptide LTX-315 Overcomes Resistance of Cancers to Immunotherapy with CTLA4 Checkpoint Blockade, Cell Death and Differentiation, vol.23, issue.6, p.100415, 2016.

Y. Yan, A. B. Kumar, H. Finnes, N. Svetomir, S. Markovic et al., « Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy, Frontiers in Immunology, vol.9, 2018.

,

H. Yao, H. Wang, C. Li, J. Fang, and J. Xu, « Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy, Frontiers in Immunology, vol.9, 2018.

. Yarchoan, . Mark, A. J. Burles, E. R. Iii, D. A. Lutz et al.,

, « Targeting Neoantigens to Augment Antitumour Immunity, vol.17, p.20922

J. Zeng, A. P. See, J. Phallen, C. M. Jackson, Z. Belcaid et al., « Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas, International Journal of Radiation Oncology*Biology*Physics, vol.86, issue.2, p.34349, 2013.

Y. Zhang, Y. Eliav, S. Shin, T. H. Schreiber, E. R. Podack et al., « B Lymphocyte Inhibition of Anti-Tumor Response Depends on Expansion of Treg but Is Independent of B-Cell IL-10 Secretion, Cancer Immunology, Immunotherapy: CII, vol.62, issue.1, p.8799, 2013.

X. Zhao, F. Kong, L. Wang, and H. Zhang, « C-FLIP and the NOXA/Mcl-1 Axis Participate in the Synergistic Effect of Pemetrexed plus Cisplatin in Human Choroidal Melanoma Cells », PLOS ONE, vol.12, issue.9, p.184135, 2017.

F. Zhou, L. Guo, H. Shi, C. Lin, . Et-jian et al., « Continuous Administration of Low-Dose Cyclophosphamide and Prednisone as a Salvage Treatment for Multiple Myeloma, Clinical Lymphoma, Myeloma and Leukemia, vol.10, issue.1, p.5155, 2010.

. Zhou, M. E. Qing, R. G. Munger, B. J. Veenstra, M. Weigel et al., « Coexpression of Tim-3 and PD-1 Identifies a CD8+ T-Cell Exhaustion Phenotype in Mice with Disseminated Acute Myelogenous Leukemia, Blood, vol.117, issue.17, p.450110, 2011.

M. W. Zimmerman, Y. Liu, S. He, A. D. Durbin, B. J. Abraham et al., « MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification, 2017.

L. Zitvogel and G. Kroemer, « Targeting PD-1/PD-L1 interactions for cancer immunotherapy, Oncoimmunology, vol.1, issue.8, p.122325, 2012.